Zalicus drops pain drug after trial failures


Nov 11 (Reuters) - Zalicus Inc said it would stopdeveloping an experimental pain drug after it failed to show abenefit over a placebo in two mid-stage trials.

The drug, called Z160, was being developed for treatingchronic pain. Zalicus said it now planned to focus on anotherpain drug, Z944.

The company's shares were halted in pre-market trading. Theyclosed at $4.69 on Friday on the Nasdaq.

View Comments (0)